FDA Authorizes Roche’s cobas pro i 601 Platform and Gabapentin Assay
The FDA granted De Novo authorization for Roche’s cobas pro i 601 platform with the Ionify Gabapentin assay. Roche plans to expand the platform by up to 22 assays as requirements are met; those assays are not yet available.
The FDA granted De Novo authorization for Roche’s cobas pro i 601 platform with the Ionify Gabapentin assay. The authorization includes a plan to expand by up to 22 assays as requirements are met; those assays are not yet available.Material DetailsContext by AI AnalystThis is an initial regulatory…